1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, 2016-2030
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Impact of Sunshine Act on Contract Sales
5.3. COVID-19 Pandemics Impact on Industry (Value Chain and Short /Mid / Long Term Impact)
6. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Service
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Service, 2016-2030
6.3.1. Personal Promotion
6.3.1.1. Promotional Sales Team
6.3.1.1.1. Dedicated Sales Team
6.3.1.1.2. Syndicated Sales Team
6.3.1.2. Key Account Management
6.3.1.3. Vacancy Management
6.3.2. Non-personal Promotion
6.3.2.1. Tele-detailing
6.3.2.2. Interactive E-detailing
6.3.2.3. Customer Service
6.3.2.4. Medical Science Liaisons
6.3.2.5. Patient Engagement Services
6.3.2.6. Others
6.3.3. Other Services
6.4. Market Attractiveness Analysis, by Service
7. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapeutic Area, 2016-2030
7.3.1. Cardiovascular Disorders
7.3.2. Oncology
7.3.3. Metabolic Disorders
7.3.4. Neurology
7.3.5. Orthopedic Diseases
7.3.6. Infectious Diseases
7.3.7. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area
8. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Service, 2016-2030
9.2.1. Personal Promotion
9.2.1.1. Promotional Sales Team
9.2.1.1.1. Dedicated Sales Team
9.2.1.1.2. Syndicated Sales Team
9.2.1.2. Key Account Management
9.2.1.3. Vacancy Management
9.2.2. Non-personal Promotion
9.2.2.1. Tele-detailing
9.2.2.2. Interactive E-detailing
9.2.2.3. Customer Service
9.2.2.4. Medical Science Liaisons
9.2.2.5. Patient Engagement Services
9.2.2.6. Others
9.2.3. Other Services
9.3. Market Value Forecast, by Therapeutic Area, 2016-2030
9.3.1. Cardiovascular Disorders
9.3.2. Oncology
9.3.3. Metabolic Disorders
9.3.4. Neurology
9.3.5. Orthopedic Diseases
9.3.6. Infectious Diseases
9.3.7. Others
9.4. Market Value Forecast, by Country, 2016-2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Service
9.5.2. By Therapeutic Area
9.5.3. By Country
10. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Service, 2016-2030
10.2.1. Personal Promotion
10.2.1.1. Promotional Sales Team
10.2.1.1.1. Dedicated Sales Team
10.2.1.1.2. Syndicated Sales Team
10.2.1.2. Key Account Management
10.2.1.3. Vacancy Management
10.2.2. Non-personal Promotion
10.2.2.1. Tele-detailing
10.2.2.2. Interactive E-detailing
10.2.2.3. Customer Service
10.2.2.4. Medical Science Liaisons
10.2.2.5. Patient Engagement Services
10.2.2.6. Others
10.2.3. Other Services
10.3. Market Value Forecast, by Therapeutic Area, 2016-2030
10.3.1. Cardiovascular Disorders
10.3.2. Oncology
10.3.3. Metabolic Disorders
10.3.4. Neurology
10.3.5. Orthopedic Diseases
10.3.6. Infectious Diseases
10.3.7. Others
10.4. Market Value Forecast, by Country/Sub-region, 2016-2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Service
10.5.2. By Therapeutic Area
10.5.3. By Country/Sub-region
11. Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Service, 2016-2030
11.2.1. Personal Promotion
11.2.1.1. Promotional Sales Team
11.2.1.1.1. Dedicated Sales Team
11.2.1.1.2. Syndicated Sales Team
11.2.1.2. Key Account Management
11.2.1.3. Vacancy Management
11.2.2. Non-personal Promotion
11.2.2.1. Tele-detailing
11.2.2.2. Interactive E-detailing
11.2.2.3. Customer Service
11.2.2.4. Medical Science Liaisons
11.2.2.5. Patient Engagement Services
11.2.2.6. Others
11.2.3. Other Services
11.3. Market Value Forecast, by Therapeutic Area, 2016-2030
11.3.1. Cardiovascular Disorders
11.3.2. Oncology
11.3.3. Metabolic Disorders
11.3.4. Neurology
11.3.5. Orthopedic Diseases
11.3.6. Infectious Diseases
11.3.7. Others
11.4. Market Value Forecast, by Country/Sub-region, 2016-2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Service
11.5.2. By Therapeutic Area
11.5.3. By Country/Sub-region
12. Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Service, 2016-2030
12.2.1. Personal Promotion
12.2.1.1. Promotional Sales Team
12.2.1.1.1. Dedicated Sales Team
12.2.1.1.2. Syndicated Sales Team
12.2.1.2. Key Account Management
12.2.1.3. Vacancy Management
12.2.2. Non-personal Promotion
12.2.2.1. Tele-detailing
12.2.2.2. Interactive E-detailing
12.2.2.3. Customer Service
12.2.2.4. Medical Science Liaisons
12.2.2.5. Patient Engagement Services
12.2.2.6. Others
12.2.3. Other Services
12.3. Market Value Forecast, by Therapeutic Area, 2016-2030
12.3.1. Cardiovascular Disorders
12.3.2. Oncology
12.3.3. Metabolic Disorders
12.3.4. Neurology
12.3.5. Orthopedic Diseases
12.3.6. Infectious Diseases
12.3.7. Others
12.4. Market Value Forecast, by Country/Sub-region, 2016-2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Service
12.5.2. By Therapeutic Area
12.5.3. By Country/Sub-region
13. Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Service, 2016-2030
13.2.1. Personal Promotion
13.2.1.1. Promotional Sales Team
13.2.1.1.1. Dedicated Sales Team
13.2.1.1.2. Syndicated Sales Team
13.2.1.2. Key Account Management
13.2.1.3. Vacancy Management
13.2.2. Non-personal Promotion
13.2.2.1. Tele-detailing
13.2.2.2. Interactive E-detailing
13.2.2.3. Customer Service
13.2.2.4. Medical Science Liaisons
13.2.2.5. Patient Engagement Services
13.2.2.6. Others
13.2.3. Other Services
13.3. Market Value Forecast, by Therapeutic Area, 2016-2030
13.3.1. Cardiovascular Disorders
13.3.2. Oncology
13.3.3. Metabolic Disorders
13.3.4. Neurology
13.3.5. Orthopedic Diseases
13.3.6. Infectious Diseases
13.3.7. Others
13.4. Market Value Forecast, by Country/Sub-region, 2016-2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Service
13.5.2. By Therapeutic Area
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by Tier and Size of companies)
14.2. Market Share Analysis/Ranking, by Company, 2020
14.3. Company Profiles
14.3.1. Ashfield (UDG Healthcare plc)
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Growth Strategies
14.3.1.3. SWOT Analysis
14.3.2. inVentiv Health, Inc. (Syneos Health)
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Growth Strategies
14.3.2.3. SWOT Analysis
14.3.3. IQVIA
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. Granard Pharmaceutical Sales & Marketing
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Vanguard Pharma, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. GTS Solution
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Growth Strategies
14.3.6.3. SWOT Analysis
14.3.7. EVERSANA
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Growth Strategies
14.3.7.3. SWOT Analysis
14.3.8. MaBiCo
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Growth Strategies
14.3.8.3. SWOT Analysis
14.3.9. QFR Solutions
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Growth Strategies
14.3.9.3. SWOT Analysis
14.3.10. Pharmaforce Ireland Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
14.3.11. Sales Focus, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Growth Strategies
14.3.11.3. SWOT Analysis
14.3.12. Amplity Health
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Growth Strategies
14.3.12.3. SWOT Analysis